In this episode, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney in Australia, and Dr Andrew Chang, Principal Retinal Specialist at the Sydney Retina Clinic and Day Surgery in Australia, share their thoughts on the optimal anti-VEGF therapy regimens to treat retinal vascular diseases, including nAMD and DME. They discuss how the best regimen should be effective in maintaining vision, proactive, individualized to the patient’s needs, and convenient for the patient. Using prctical examples from their own clinics, Professor Mitchell and Dr Chang explore how to treat different patients with different levels of starting visual acuity, and how treatments for retinal vascular diseases have changed over time.  This podcast is produced in partnership with the Vision Academy, a group of internationally renowned retinal experts who collaborate to provide guidance to the retinal community on clinical challenges in ophthalmology and controversies in care.  The Vision Academy viewpoints providing guidance on clinically challenging situations, and other important resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before subscribing. If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their thoughts on bilateral retinal disease and treatment, how to optimize treatment of patients with nAMD with macular neovascularization subtypes, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence. SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!    Further information on other studies mentioned in this episode: ARIES study: Mitchell et al., Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen for Neovascular Age-Related Macular Degeneration. The ARIES Study: A Randomized Clinical Trial https://journals.lww.com/retinajournal/Fulltext/2021/09000/EFFICACY_AND_SAFETY_OF_INTRAVITREAL_AFLIBERCEPT.15.aspx July 2023 MA-PFM-OPHT-ALL-1183-1